U.S. Markets close in 1 hr 59 mins

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
112.14-4.90 (-4.18%)
As of 2:01PM EDT. Market open.
People also watch
BMRNSGENACORACADALXN
Full screen
Previous Close117.04
Open117.40
Bid112.58 x 100
Ask112.75 x 100
Day's Range112.08 - 117.40
52 Week Range31.38 - 118.40
Volume847,110
Avg. Volume1,249,592
Market Cap10.29B
Beta3.21
PE Ratio (TTM)-21.89
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Alnylam Pharmaceuticals CEO: Trial results open up the do...
    CNBC Videos5 days ago

    Alnylam Pharmaceuticals CEO: Trial results open up the do...

    Alnylam Pharmaceuticals CEO John Maraganore discusses his company's successful drug trial to treat a rare nerve disorder, and what he sees for the underlying technology. With CNBC's Meg Tirrell.

  • Barrons.comyesterday

    Gene Therapy: A Big Week for Many Names

    It’s been a big week for the gene therapy universe. Of course, there’s the latest Barron’s cover story, which details the emerging medical revolution and highlights three stocks -- AveXis (AVXS), Regenxbio (RGNX), and Spark Therapeutics (ONCE) -- that have big stakes in what is widely considered one of the most exciting areas in the biotechnology arena. Last week, Ultragenyx Pharmaceutical (RARE) offered to buy Dimension Therapeutics (DMTX) for at $5.50 per share in cash.

  • Thomson Reuters StreetEvents2 days ago

    Edited Transcript of ALNY earnings conference call or presentation 9-Aug-17 8:30pm GMT

    Q2 2017 Alnylam Pharmaceuticals Inc Earnings Call